Le et al., 2016 - Google Patents
Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL therapyLe et al., 2016
View PDF- Document ID
- 13162770718464328788
- Author
- Le K
- Thibult M
- Just-Landi S
- Pastor S
- Gondois-Rey F
- Granjeaud S
- Broussais F
- Bouabdallah R
- Colisson R
- Caux C
- Ménétrier-Caux C
- Leroux D
- Xerri L
- Olive D
- Publication year
- Publication venue
- Cancer Research
External Links
Snippet
The prognosis of follicular lymphoma (FL) patients is suspected to be influenced by tumor- infiltrating regulatory T cells (Treg). The mechanism of Treg enrichment in FL and their impact on malignant FL B cells remains to be elucidated. We analyzed 46 fresh lymph node …
- 102100014733 ICOSLG 0 title abstract description 86
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Le et al. | Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL therapy | |
Timperi et al. | Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer | |
Wu et al. | Blockade of TIGIT/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma | |
Catakovic et al. | TIGIT expressing CD4+ T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia | |
Kawano et al. | Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression | |
Toker et al. | Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma | |
Lim et al. | The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma | |
Abd Hamid et al. | Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses | |
Foulds et al. | Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer | |
Mittal et al. | Local and systemic induction of CD4+ CD25+ regulatory T-cell population by non-Hodgkin lymphoma | |
Poschke et al. | Immature immunosuppressive CD14+ HLA-DR−/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | |
Arroyo Hornero et al. | CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells | |
Singh et al. | ILT3 (LILRB4) promotes the immunosuppressive function of tumor-educated human monocytic myeloid-derived suppressor cells | |
Semeraro et al. | Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients | |
Woo et al. | Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer | |
Cooley et al. | A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature | |
Muccio et al. | Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents | |
Bergmann et al. | T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease | |
Audia et al. | Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes | |
Seddiki et al. | Persistence of naive CD45RA+ regulatory T cells in adult life | |
Bloch et al. | Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages | |
Strauss et al. | Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with rapamycin | |
Harlin et al. | Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites | |
Roussel et al. | Functional characterization of PD1+ TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade | |
Fregni et al. | Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy |